仁度生物：2025年营收1.62亿元，净利润同比增加1732.13万元

Core Viewpoint - The company announced a projected revenue of 162.06 million yuan for 2025, representing a year-on-year decrease of 8.62% [1] - The net profit attributable to the parent company is expected to be 9.51 million yuan, an increase of 17.32 million yuan year-on-year [1] - The non-recurring net profit is projected to be -12.28 million yuan, an increase of 7.28 million yuan year-on-year [1] Financial Performance - Total assets at the end of the reporting period are expected to be 989.51 million yuan, a decrease of 0.49% compared to the beginning of the period [1] - Equity attributable to the parent company's owners is projected to be 913.33 million yuan, an increase of 0.16% from the beginning of the period [1] Performance Drivers - The changes in performance are primarily attributed to cost reduction, efficiency improvement, expense control, and the reversal of certain impairment losses [1]